Despite the equivocal results of the ABSORB trials to date, the key question remains what happens over the long term with these devices.
Lead investigator of the pivotal study of the new bioresorbable stent explains the nuanced interim results (straight from ACC.17) and what to expect next.
Make room in your schedule at the American College of Cardiology meeting for key presentations ranging from the SPIRE 1 and 2 trials to ABSORB III two-year results and more.
This free Thursday dinner symposium at ACC.17 can help attendees make the most of the many advancements discussed at the larger meeting. The course directors explain why you shouldn’t miss it.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
An FDA advisory panel just recommended approval of what may be the nation’s first bioresorbable stent. Here’s why an ABSORB III trial investigator wasn’t surprised that interim results didn’t find it superior to a standard DES.